CureMeta Company Profile
CureMeta, founded in 2012 and based in Mansfield, MA, is a privately held biotech company specializing in antibody-based cancer therapeutics targeting metastatic and stem cell-driven cancers, with expertise in monoclonal antibody discovery, antibody-drug conjugates, and humanized IgG1 engineering, currently in preclinical trial stages and backed by an accelerator/incubator, holding 19 patent documents including active and pending patents related to podocalyxin and TRA-related antibodies for anti-cancer treatments.
Overview
CureMeta is a developer of antibody-based cancer therapeutics focused on targeting metastatic and stem cell-driven cancers. The company specializes in:
- Monoclonal antibody discovery
- Antibody-drug conjugate development
- Humanized immunoglobulin G1 (IgG1) antibody engineering
- Cancer stem cell targeting technology
- Embryonic antigen-specific therapeutic antibodies
- Preclinical cancer treatment research
- Clinical trial preparation activities
These capabilities enable oncology researchers and healthcare providers to develop targeted treatments for metastatic gastric and pancreatic cancers with reduced impact on healthy tissues.
Company Details
- Year Founded: 2012
- Status: Private
- Employees: 2
- Latest Deal Type: Accelerator/Incubator
- Primary Industry: Drug Discovery
- Other Industries: Biotechnology
- Verticals: HealthTech, Life Sciences, Oncology
- Ownership Status: Privately Held (backing)
- Financing Status: Accelerator/Incubator Backed
Corporate Office
241 Francis Avenue
Bio Mansfield Incubator
Mansfield, MA 02148
United States
Website: www.curemeta.com
Valuation & Funding
- Deal Type: Accelerator/Incubator
- Status: Completed
- Stage: Pre-Clinical Trials
Patents
- Total Documents (Applications and Grants): 19
- Total Patent Families: Not specified
- Granted: 6
- Pending: 3
- Expiring in next 12 months: Not specified
Recent Patent Activity
- JP-2022062018-A: Podocalixin and tra-related antibodies, preparation methods, and use as anti-cancer therapeutic agents (Active, filed 14-Mar-2016)
- JP-2019512548-A: Podocalyxin and tra-related antibodies, methods of preparation and use as anti-cancer therapeutics (Pending, filed 14-Mar-2016)
- JP-7531224-B2: Podocalyxin and tra-related antibodies, preparation method, and use as anticancer therapeutic agents (Active, filed 14-Mar-2016)
- AU-2017234134-A1: Podocalyxin and tra-related antibody, methods of preparation and uses as an anti-cancer therapeutic agent (Active, filed 14-Mar-2016)
- AU-2017234134-B2: Podocalyxin and tra-related antibody, methods of preparation and uses as an anti-cancer therapeutic agent (Active, filed 14-Mar-2016, Technology: C07K16/2896)
Investors
- Bioincubator (Accelerator/Incubator)
FAQs
When was CureMeta founded?
CureMeta was founded in 2012.
Where is CureMeta headquartered?
CureMeta is headquartered in Mansfield, MA.
What is the size of CureMeta?
CureMeta has 2 total employees.
What industry is CureMeta in?
CureMeta’s primary industry is Drug Discovery.
Is CureMeta a private or public company?
CureMeta is a Private company.
Who are CureMeta’s investors?
Bioincubator has invested in CureMeta.